Association between TCF7L2 Genotype and Glycemic Control in Diabetic Patients Treated with Gliclazide

Table 1

Clinical and biochemical characteristics of the patients according to treatment with gliclazide (Group 1) or K_ATP channel AB-site binding sulfonylureas (Group 2).

	Entire group (𝑛=101)	Group 1 (𝑛=55)	Group 2 (𝑛=46)	𝑃
Sex (males/females)	50/51	29/26	21/25	0.921
Age (years)	61.9±1.0	62.3±1.2	61.4±1.7	0.673
Diabetes duration (years)	2.3±0.2	2.3±0.2	2.4±0.5	0.839
Baseline BMI (kg/m^2)	30.6±0.40	30.7±0.5	30.5±0.6	0.729
SU dose (% max dose)	47.0±1.9	44.5±2.4	49.8±2.9	0.160
Baseline HbA1c (%)	8.04±0.09	7.91±0.11	8.20±0.15	0.122
HbA1c after 6 months (%)	6.99±0.06	6.89±0.09	7.11±0.09	0.094
ΔHbA1c (%)	1.05±0.08	1.03±0.10	1.09±0.11	0.717

BMI: body mass index; SU: sulfonylurea derivatives; 𝑃 values for difference between Group 1 and Group 2.